AstraZeneca v. TTY Biopharm: Taiwan Court Rules Generic’s “Skinny Label” Does Not Infringe

On June 11, 2025, Taiwan’s Intellectual Property and Commercial Court (IPCC) issued a decision in a pharmaceutical patent dispute between AstraZeneca AB and TTY Biopharm Company Limited (Case №113-Min-Zhuan-Su-Zi №62). The Court dismissed the plaintiff’s, AstraZeneca’s, request to prevent the defendant, TTY Biopharm, from marketing its generic drug. The ruling provides important insights into how Taiwanese courts approach patent term extensions, “skinny labels,” and the argument of potential off-label use in infringement cases.

The Patent and the Carve-Out Strategy

The dispute centered on a patent held by AstraZeneca for its breast cancer drug, Faslodex (active ingredient: Fulvestrant). While the original patent had expired, its term was extended for a specific medical use: “for the treatment of postmenopausal women with estrogen receptor-positive, locally advanced or metastatic breast cancer who have not previously received endocrine therapy.” This is often referred to as a “first-line” treatment.

The defendant, TTY Biopharm, sought marketing approval for its generic version of the drug, named “Fustron.” To navigate AstraZeneca’s patent, TTY Biopharm employed a “skinny label” or “carve-out” strategy. Its proposed drug label deliberately excluded the patented first-line indication. Instead, the label listed only indications that were no longer under patent protection, such as second-line treatments for patients whose disease had progressed despite prior anti-estrogen therapy.

AstraZeneca argued that even with the skinny label, there was a high risk of infringement. It contended that physicians, aware that the active ingredient is identical, would inevitably prescribe the more affordable generic drug for the patented first-line use, an act known as “off-label” prescription.

The Court’s Analysis

The IPCC rejected AstraZeneca’s arguments and sided with the generic manufacturer. The judgment’s reasoning was clear and methodical.

No Literal Infringement

The Court first conducted a direct comparison between the patent claim and the generic drug’s proposed use. It concluded that the generic product did not literally infringe the patent’s extended scope. The judgment stated:

“the approved extended scope of the patent is for first-line treatment… The generic drug’s three indications are for second-line or subsequent treatment… Therefore, the two are clearly different scopes, and the accused generic drug cannot be literally read by the patent’s technical feature B.”

The court emphasized that the patient populations for first-line and second-line treatments are distinct and easily distinguishable in clinical practice, making the carve-out medically and practically reasonable.

The Off-Label Use Argument is Insufficient

The core of the decision rested on the court’s analysis of potential off-label use. While acknowledging that physicians can and do prescribe drugs off-label, the court found that this possibility alone does not constitute patent infringement by the generic manufacturer. The judgment highlighted several key points:

  • Lack of Inducement: The defendant’s proposed drug label did not contain any information, clinical trial data, or instructions that would encourage or teach physicians to use the generic drug for the patented first-line indication. The court noted, “the defendant has not cited clinical trial results for the first-line treatment indication in the proposed package insert for the accused generic drug, and there is no concern that it would imply to medical personnel that the accused generic drug should be used for the first-line treatment.”
  • Physician’s Independent Judgment: Off-label use is a physician’s personal and professional decision, governed by separate medical regulations and principles. The court was unwilling to attribute the independent actions of a physician back to the manufacturer, which had explicitly limited its product’s indications.
  • Legality of Skinny Labels: The court affirmed that the skinny label strategy is a recognized and intended feature of Taiwan’s pharmaceutical patent linkage system. This mechanism is designed to balance the rights of patent holders with the public’s need for access to more affordable medicines for non-patented uses.
  • No Substantial Causation: AstraZeneca argued that TTY Biopharm knew that off-label infringement would occur. However, the Court determined that the causal link was too weak. It found that a patient’s potential use of the generic drug for a first-line indication was contingent on many factors: a physician’s decision to go off-label, the availability of other reimbursed drugs, and the patient’s own choice among multiple branded and generic options. This chain of events was deemed “merely a coincidental fact” and did not meet the legal standard of substantial causation required for infringement.

My Takeaway

The decision sets a high bar for patent holders trying to block generics based on the “risk” of off-label use. A mere possibility or statistical likelihood of off-label prescription is not enough. The patent holder would likely need to show that the generic manufacturer is actively inducing or promoting the infringing use, a claim for which there was no evidence in this case.

Source: https://judgment.judicial.gov.tw/FJUD/data.aspx?ty=JD&id=IPCV%2C113%2C%E6%B0%91%E5%B0%88%E8%A8%B4%2C62%2C20250611%2C2